Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-19
2000-10-17
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142342, 51425202, A61K 31519
Patent
active
061332712
ABSTRACT:
Benzothienopyrimidine derivatives for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and specifically for arresting and treating neoplasia, including precancerous and cancerous lesions of formula I: ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, A, OA, alkenyl, alkynyl, --NO.sub.2, --CF.sub.3 or halogen, with the proviso that one of R.sub.1 or R.sub.2 is not hydrogen; R.sub.3 and R.sub.4 are independently selected from the group consisting of hydrogen, A, --OA, halogen, --NO.sub.2, --NH.sub.2, --NHA or --NAA', or R.sub.3 and R.sub.4 are together form a moiety selected from the group consisting of --O--CH.sub.2 --CH.sub.2 --, --O--CH.sub.2 --O-- or --O--CH.sub.2 --CH.sub.2 --O; X is selected from the group consisting of an unsubstituted or a substituted 5-7 membered saturated or unsaturated ring, wherein the ring is selected from the group consisting of phenyl, cyclopentyl, cyclohexyl, cycloheptyl, furyl, dioxolanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridyl, piperidinyl, morpholinyl, pyranyl, dioxanyl, pyridazinyl, pyrimidinyl, piperazinyl, quinolyl, and isoquinolyl and wherein the substitutents on the "X" ring are one or two selected from the group consisting of lower alkyl, COOH, --COOA, --CONH.sub.2, --CONAA', --CONHA, --CN, --CH.sub.2 COOH or --CH.sub.2 CH.sub.2 COOH; A and A' are independently selected from the group consisting of hydrogen or C.sub.1-6 alkyl; and n is 0, 1, 2 or 3; and physiologically acceptable salts thereof.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3161654 (1964-12-01), Shen
patent: 3322755 (1967-05-01), Roch et al.
patent: 3517005 (1970-06-01), Cronin et al.
patent: 3594480 (1971-07-01), Cronin et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3780040 (1973-12-01), Schnettler et al.
patent: 3812127 (1974-05-01), Cronin et al.
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3865840 (1975-02-01), Carson
patent: 3920636 (1975-11-01), Takahasi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4076711 (1978-02-01), Ganguly et al.
patent: 4079057 (1978-03-01), Juby et al.
patent: 4098788 (1978-07-01), Crenshaw et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4102885 (1978-07-01), Crenshaw et al.
patent: 4138561 (1979-02-01), Crenshaw et al.
patent: 4146716 (1979-03-01), Cox et al.
patent: 4161595 (1979-07-01), Kaplan et al.
patent: 4171363 (1979-10-01), Crenshaw et al.
patent: 4196207 (1980-04-01), Webber et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4209623 (1980-06-01), Juby
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 4457927 (1984-07-01), Biere et al.
patent: 4460590 (1984-07-01), Moller
patent: 4460591 (1984-07-01), DeGraw et al.
patent: 4880810 (1989-11-01), Lowe, III et al.
patent: 4885301 (1989-12-01), Coates
patent: 4923874 (1990-05-01), McMahon et al.
patent: 4971972 (1990-11-01), Doll et al.
patent: 5073559 (1991-12-01), Coates
patent: 5091431 (1992-02-01), Tulshian et al.
patent: 5147875 (1992-09-01), Coates et al.
patent: 5175151 (1992-12-01), Afonso et al.
patent: 5223501 (1993-06-01), Chakravarty et al.
patent: 5250535 (1993-10-01), Verheyden et al.
patent: 5254571 (1993-10-01), Coates et al.
patent: 5280026 (1994-01-01), Brown et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5376683 (1994-12-01), Klar et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5696159 (1997-12-01), Gross et al.
patent: 5728563 (1998-03-01), Toshio et al.
patent: 5756818 (1998-05-01), Buchmann et al.
patent: 5852035 (1998-12-01), Pamukcu et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 5869486 (1999-02-01), Lee et al.
patent: 5874440 (1999-02-01), Pamukcu et al.
patent: 5984911 (1999-09-01), Pamukcu et al.
Blaya, C. et al., Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression, European Journal of Pharmacology, 354, pp. 99-104 (1998).
Chang, W. et al., Sulindac Sulfone Modulates the Expression and Cellular Localization of b-Catenin in Human Colon Carcinoma Cells, Digestive Disease Week, Apr. 1, 1999.
Earnest, D. et al., Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention, Journal of Cellular Biochemistry, Supplement 161:156-166 (1992).
Easwaran, V. et al., The Ubiquitin-Proteasome Pathway and Serine Kinase Activity Modulate Adenomatous Polyposis Coli Protein-mediated Regulation of .beta.-Catenin-Lymphocyte Enhancer-binding Factor Signaling, The Journal of Biological Chemistry, vol. 274, No. 23, pp. 16641-16645, Jun. 4, 1999.
Jiang, X. et al., Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 11236-11241, Oct. 1996.
Korinek, V. et al., Constitutive Transcriptional Activation by a .beta.-Catenin-Tcf Complex in APC.sup.-/- Colon Carcinoma, Science, vol. 175, pp. 1784-1786, Mar. 21, 1997.
Mahmoud, N. et al., Apc Gene Mutation is Associated with a Dominant-Negative Effect upon Intestinal Cell Migration, Cancer Research 57, pp. 5045-5050, Nov. 15, 1997.
Mahmoud, N. et al., Genotype-Phenotype Correlation in Murine Apc Mutation: Differences in Enterocyte Migration and Response to Sulindac, Cancer Research 59, pp. 353-359, Jan. 15, 1999.
Morin, P. et al., Activation of .beta.-Catenin-Tcf Signaling in Colon Cancer by Mutations in .beta.-Catenin or APC, Science, vol. 275, pp. 1787-1789, Mar. 21, 1997.
Peifer, M., .beta.-Catenin as Oncogene: The Smoking Gun, Science, vol. 275, pp. 1752-1753, Mar. 21, 1997.
Rubinfeld, B. et al., Stabilization of .beta.-Catenin by Genetic Defects in Melanoma Cell Lines, Science, vol. 275, pp. 1790-1792, Mar. 21, 1997.
Rochus et al. CA Abstract Accession No. 1998:268506, 1998.
Rochus et al CA Abstract Accession No. 1998:126255, 1998.
Boehm et al. CA Abstract Accession No. 1987:156389, 1986.
Boehm et al. CA Abstract Accession No. 1986:186437, 1986.
Waddell, w.R. et al., Am. J. Surgery, vol. 157, pp. 175-179 (1989).
Gonzaga, R.A.F. et al., The Lancet, Mar. 30, 1985, p. 751.
Waddell, W.R. et al., J. Surg. Oncology, vol. 24, pp. 83-87 (1983).
Federation Proceedings (1972) of the Federation of American Societies for Experimental Biology abstract Nos. 2044 and 2045.
Gilman, S.C. et al., Nonsteroidal Anti-inflammatory Drugs in Cancer Therapy, (circa 1985).
Brogden, R.N. et al., Drugs, vol. 16, pp. 97-114 (1978).
Hucker, H.B. et al., Drug Metabolism & Disposition, vol. 1, No. 6, pp. 721-736 (1973).
Shen, T.Y. et al., Chemical and Biological Studies on Indomethacin, Sulindac and Their Analogs, pp. 107-178 (circa 1975).
Duggan, D.E. et al., Clin. Pharm. & Therapeutics, vol. 21, No. 3, pp. 326-335 (1976).
Duggan, D.E. et al., J. Pharm. & Exper. Therap., vol. 201, No. 1, pp. 8-13 (1977).
Glavin, G.B. et al., Toxicology and Applied Pharmacology, vol. 83, pp. 386-389 (1986).
Moorghen, M. et al., Journal of Pathology, vol. 156, pp. 341-347 (1988).
Moorghen, M. et al., Acta Histochemica, Suppl.-Band XXIX, S. 195-1999 (1990).
Bjarnason et al., Gastroenterology, vol. 94, No. 4, pp. 1070-1074 (1988).
Badrieh, Y., et al., Chem. Ber., vol. 125, pp. 667-674 (1992).
Silvola, J. et al., Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity, Agents and Actions, vol. 12.4, pp. 516-520 (1982).
Curtis-Prior, P.B. et al., Cyclic Nucldeotide Phosphodiesterase Activity of Human Normal and Carcinomatous Lung Tissue, The Lancet, pp. 1225-1225 Dec. 4, 1976.
Pepin, P. et al., Effects of Sulindac and Oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyri
Pamukcu Rifat
Piazza Gary A.
Cell Pathways Inc.
Raymond Richard L.
Stevenson Robert W.
LandOfFree
Method for inhibiting neoplastic cells and related conditions by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting neoplastic cells and related conditions by, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting neoplastic cells and related conditions by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-469199